Intravenous transfer of autologous NK cells. Dose-escalation study with three groups 1)5x108 cells 3 patients 2)1x109 cells 3 patients 3)2x10*9 cells 3 patients

2 trials

Sponsors

Cancer ImmunoCell Regulation, Kyoto Prefectural Univercity of Medicine, Kyoto Prefectural University of Medicine

Conditions

inoperable advance and recurrence stomach and colon cancer combined with IgG1 antibody in chemotherapyrefractory digestive/gastrointestinal cancer

Phase 1

Phase 1 clinical study of highly purified natural killer (NK) cell infusion for patients with refractory digestive/gastrointestinal cancer to standard therapy

Active, not recruitingJPRN-UMIN000007527

Cancer ImmunoCell Regulation, Kyoto Prefectural Univercity of Medicinerefractory digestive/gastrointestinal cancer

Start: 2012-04-01Target: 9Updated: 2026-06-29

Unknown Phase

The phase I clinical study about the combined therapy, high purity natural killer (NK) cell therapy and IgG1 antibody to inoperable advance and recurrence digestive cancer

Active, not recruitingJPRN-UMIN000013378

Kyoto Prefectural University of Medicineinoperable advance and recurrence stomach and colon cancer combined with IgG1 antibody in chemotherapy

Start: 2014-07-01Target: 9Updated: 2026-06-29

Related Papers

Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer.

2015-08-25199 citations